Fennec Pharmaceuticals Reports Record 2025 Sales, 50% Growth, and Eliminates All Debt
Summary
Fennec Pharmaceuticals announced strong full-year 2025 financial results, including record PEDMARK® sales growth and a significantly strengthened balance sheet with all debt repaid.
Key Events
-
Record 2025 Product Sales
Reported full-year 2025 net PEDMARK® product sales of $44.6 million, representing 50% year-over-year growth. Q4 2025 net product sales were $13.8 million, a 75% increase over Q4 2024.
-
Strengthened Balance Sheet
Completed $42 million in equity offerings and fully redeemed all outstanding debt, resulting in $36.7 million in cash and cash equivalents and $0 debt outstanding as of December 31, 2025.
-
Clinical Program Expansion
Presented new real-world data supporting PEDMARK® use in adults with head and neck cancer and initiated two new institution-led clinical studies to expand its application.
-
Positive Japan Trial Results
Announced positive topline results from an investigator-initiated Phase 2/3 clinical trial of PEDMARK® in Japan, demonstrating hearing protection without compromising efficacy, and is pursuing registration.
Analysis
Fennec Pharmaceuticals delivered a strong financial and operational update for full-year 2025. The company achieved record net product sales for PEDMARK®, demonstrating significant year-over-year growth and increasing adoption. Crucially, Fennec substantially strengthened its financial position by completing $42 million in equity offerings and fully redeeming all outstanding debt, resulting in a healthy cash balance and zero debt. This de-risks the balance sheet and provides a solid foundation for continued commercial expansion and clinical development. Positive clinical updates, including new real-world data and the initiation of additional studies, further support the long-term potential of PEDMARK®.
At the time of this filing, FENC was trading at $6.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $205.5M. The 52-week trading range was $4.68 to $9.92. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.